[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now",
    "summary": "We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]",
    "url": "https://finnhub.io/api/news?id=6b83cd0ff946fa8354c36da4f6e5b1f9a9f2b818e4e260429823a0376852b5f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732060310,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now",
      "id": 131510064,
      "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]",
      "url": "https://finnhub.io/api/news?id=6b83cd0ff946fa8354c36da4f6e5b1f9a9f2b818e4e260429823a0376852b5f3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7908a480e735d785827eb81da34f05651b7863874d0d96600c093b08e763e8c0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732034700,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131510900,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7908a480e735d785827eb81da34f05651b7863874d0d96600c093b08e763e8c0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ETCompany ParticipantsRyan Crowe - SVP,...",
    "url": "https://finnhub.io/api/news?id=3e8cb69b21c3b807ddd98c6929fdb6b798d2e36b18790b60671337e308fa2f0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732032549,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)",
      "id": 131491959,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ETCompany ParticipantsRyan Crowe - SVP,...",
      "url": "https://finnhub.io/api/news?id=3e8cb69b21c3b807ddd98c6929fdb6b798d2e36b18790b60671337e308fa2f0c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: The Biotech Stock To Buy Now",
    "summary": "Regeneron's stock drop presents a buying opportunity amidst regulatory and market uncertainty. Click here to read an analysis of REGN stock now.",
    "url": "https://finnhub.io/api/news?id=ec926e3aacec8b5c6ef40840a479dc6ddac11c77d42e2b9f70819b18abb8015a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732031575,
      "headline": "Regeneron: The Biotech Stock To Buy Now",
      "id": 131491969,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron's stock drop presents a buying opportunity amidst regulatory and market uncertainty. Click here to read an analysis of REGN stock now.",
      "url": "https://finnhub.io/api/news?id=ec926e3aacec8b5c6ef40840a479dc6ddac11c77d42e2b9f70819b18abb8015a"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3",
    "summary": "Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI (in $A). It was down 5.59% in September vs. -0.35% for the index. The market rose in the […]",
    "url": "https://finnhub.io/api/news?id=327b2c5d5416b980daa522186f8276b05df8a851144ab4c1c703e32eb2ee17fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732029400,
      "headline": "Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3",
      "id": 131491473,
      "image": "https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI (in $A). It was down 5.59% in September vs. -0.35% for the index. The market rose in the […]",
      "url": "https://finnhub.io/api/news?id=327b2c5d5416b980daa522186f8276b05df8a851144ab4c1c703e32eb2ee17fe"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
    "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015683,
      "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
      "id": 131474886,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429734/image_107429734.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
      "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12"
    }
  }
]